BRAF and neoplasm: Interestingly, in melanoma, downregulation of MHC-I has been linked to the enrichment of a mesenchymal/invasive phenotypic profile in tumor cells, implying a coalescence of the mechanisms that confer resistance to both immunotherapy and BRAF inhibition [27].